🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Riociguat-Discontinue Effects on Right HEART in CTEPH (RED-HEART)

RecruitingPhase 3Ages 18 Years - anyAllSuqiao Yang
NCT06922240 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Riociguat and balloon pulmonary angioplasty (BPA) are established standard-of-care interventions for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) with comparable evidence levels. However, the optimal combined treatment strategy remains unclear. Specifically, there is no consensus on whether riociguat should be continued long-term after achieving hemodynamic stability with BPA. Additionally, the long-term effects of riociguat discontinuation on right ventricular (RV) structure and function remain poorly characterized, particularly due to the lack of comprehensive noninvasive evaluations integrating cardiac magnetic resonance (CMR) and echocardiography. This prospective study aims to determine the hemodynamic impact of riociguat discontinuation in inoperable CTEPH patients who have achieved BPA treatment endpoints using right heart catheterization (RHC). Evaluate RV rem

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥18 years old * CTEPH was diagnosed and one of the following three factors was met: Pulmonary endarterectomy was technically impossible; Pulmonary endarterectomy is technically feasible, but the risk-benefit ratio is poor; Residual/recurrent pulmonary hypertension after pulmonary endarterectomy * Subjects had been treated with BPA and had received a stable dose of riociguat for ≥12 weeks * mPAP \< 30mmHg * Male subjects and female subjects of reproductive age are required to use effective contraception for at least 28 days after signing the informed consent form. Male subjects are not allowed to donate sperm and female subjects are not allowed to breastfeed. * Subjects voluntarily sign written informed consent Exclusion Criteria: * Severe hepatic and renal insufficiency (Child-Pugh Grade C/creatinine clearance \< 30ml/min·1.73m²) * The presence of severe infectious disease or severe bleeding tendency * Combined with pulmonary hypertension of other types than CTEPH * Other pulmonary hypertension targeting drugs are being used * The expected survival time with cancer or other diseases is less than 6 months * Pregnancy, lactation * Subjects are currently participating in an interventional clinical trial * In the investigator's judgment, a subject's medical abnormality, physical condition, or medical history may affect his or her ability to participate in or complete the study
💊

What it tests

  • Riociguat
  • Routine Treatment
📍

Where

3 sites
Beijing Chao-Yang Hospital
Beijing, China
China-Japan Friendship Hospital
Beijing, China
Beijing Anzhen Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy